TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.

As the non-muscle invasive space is carved up, Aura tries to seize part of it.

The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.